Browse our anti-CPT1A (CPT1A) Antibodies

Human Carnitine Palmitoyltransferase 1A (Liver) (CPT1A) interaction partners

1. High expression level of CPT1A is associated with breast cancer.

2. The rs80356779, a p.Pro479Leu variant in CPT1A, was highly significantly associated with a range of fatty acid metabolism measures in a population-based sample from Greenland.

3. associations between methylation in CPT1A and lipoprotein measures highlight the epigenetic role of this gene in metabolic dysfunction.

4. Homozygosity for the arctic variant is associated with increased risk of infant mortality, which may be mediated in part by an increase in infectious disease risk. Further studies are needed to determine whether the association we report represents a causal association between the CPT1A arctic variant and infectious disease-specific mortality

5. We provide evidence that the downregulation of hsa (show CD24 Antibodies)-miR (show MLXIP Antibodies)-124-3p, hsa (show CD24 Antibodies)-miR (show MLXIP Antibodies)-129-5p and hsa (show CD24 Antibodies)-miR (show MLXIP Antibodies)-378 induced an increase in both expression and activity of CPT1A, CACT (show SLC25A20 Antibodies) and CrAT (show CRAT Antibodies) in malignant prostate cells.

6. The recent findings and the current understanding of fatty acid oxidation and CPT1A in cancer have been summarized thus providing theoretical basis for this enzyme as an emerging potential molecular target in cancer therapeutic intervention. (Review)

7. Methylation of a CpG site in CPT1A is associated with circulating adiponectin levels, likely in an obesity-dependent manner, in three population-based adult cohorts of European descent.

8. Furthermore, given the already low abundance of Cpt1b (show CPT1B Antibodies) in white adipose tissue, it is unlikely that decreases in its expression can quantitatively decrease whole body energy expenditure enough to contribute to an obese phenotype.

9. Data show that in the absence of indoleamine 2,3-dioxygenase (IDO (show IDO1 Antibodies)) inhibition, fatty acid oxidation increased along with increased activity of carnitine palmitoyltransferase I (CPT1).

10. our results proved CPT1A as a potential prognosticator and therapeutic target for AML (show RUNX1 Antibodies).

Pig (Porcine) Carnitine Palmitoyltransferase 1A (Liver) (CPT1A) interaction partners

1. acetate is the primary product of hepatic mitochondrial beta-oxidation in Sus scrofa and that regulation during early development is mediated primarily via kinetic modulation of CPT I (show CPT1B Antibodies)

Cow (Bovine) Carnitine Palmitoyltransferase 1A (Liver) (CPT1A) interaction partners

1. This study evaluated the effects of nonesterified fatty acids and glucose on carnitine palmitoyltransferase-I (CPT-I) mRNA expression in cultured bovine hepatocytes using real-time reverse transcription polymerase chain reaction and ELISA methods.

2. It was conclude that suppression of CPT (show DHDDS Antibodies) activity by positive energy balance appears to be specific for the liver in mid-lactating dairy cows.

Mouse (Murine) Carnitine Palmitoyltransferase 1A (Liver) (CPT1A) interaction partners

1. Alogliptin increased hepatic mRNA expression levels associated with fatty acid oxidation. In addition, the results of the present study suggested that ALO (show LMX1B Antibodies) promotes CPT1a expression via Thr172 phosphorylation of AMPKalpha (show GRK4 Antibodies).

2. Furthermore, given the already low abundance of Cpt1b (show CPT1B Antibodies) in white adipose tissue, it is unlikely that decreases in its expression can quantitatively decrease whole body energy expenditure enough to contribute to an obese phenotype.

3. beneficial effects of muscle CPT1mt expression suggest that a direct modulation of the malonyl-CoA/CPT1 partnership in skeletal muscle could represent a potential strategy to prevent obesity-induced insulin (show INS Antibodies) resistance

4. The data suggest that AMPK (show PRKAA1 Antibodies) is not required for the regulation of the intermediate filament interaction with CPT-I during exercise.

5. these results demonstrated that L-carnitine ameliorated liver inflammation and serum pro-inflammatory markers in cancer cachexia through regulating CPT I-dependent PPARg (show PPARG Antibodies) signaling

6. -Carnitine exerts its ameliorative effects in cancer cachexia in association with the PPAR-gamma (show PPARG Antibodies) signaling pathway.

7. Data show that peroxisome-proliferator-activated receptor beta (show PPARD Antibodies)/delta (PPARbeta (show PPARD Antibodies)/delta) activation restored the lipid-induced endothelial dysfunction by up-regulation of carnitine palmitoyltransferase)-1 (CPT-1).

8. Our results indicated that exercise-induced CPT1b (show CPT1B Antibodies) expression was at least in part mediated by HDAC5 (show HDAC5 Antibodies)/MEF2A (show MEF2A Antibodies) interaction.

9. an environment-dependent structural switch underlies the regulation of carnitine palmitoyltransferase 1A

10. miR (show MLXIP Antibodies)-370 acting via miR (show MLXIP Antibodies)-122 may have a causative role in the accumulation of hepatic triglycerides by modulating initially the expression of SREBP-1c (show SREBF1 Antibodies), DGAT2 (show DGAT2 Antibodies), and Cpt1alpha.